|
Company
|
 |
|
Mission & Strategy | Management |
Scientific Advisory Board |
Board of Directors
| Collaborations |
Company's Milestones |
Contact Us |
Email Alerts
|
|
|
Management
Proneuron's management team has experience in most major disciplines, including biomedical research, product development, international marketing, business development and finance.
Dale S. Miller, Executive Chairman  Mr. Miller is the founder and managing partner of Miller & Holguin, a Los Angeles based law firm specializing in corporate securities and health care regulatory law, established in 1984. Mr. Miller is the Executive Chairman of Proneuron and served as its Chief Executive Officer for its first five years of operations. Mr. Miller is also the co-manager of Hudson Investment Group and is a board member of various other companies.
Nir Nimrodi,
Chief Executive Officer
Mr. Nimrodi joined the Proneuron team in the beginning of
2002 after serving for three years as the CEO at Mindsense Biosystems,
a biotechnology company positioned at the crossroad between
modern biology and psychiatry. Prior to Mindsense, he held several
senior management positions at Teva Pharmaceutical Industries
Ltd. (Nasdaq: TEVA). Mr. Nimrodi earned a B.A. in economics
and an MBA from Tel Aviv University. Dr. Eti Yoles,
VP Product Research & Development
Dr. Yoles is a PhD in neurobiology from Bar-Ilan University,
Ramat-Gan, Israel in 1990. Dr. Yoles graduated cum laudae, based
on her thesis on age related brain ionic and metabolic responses
to stress conditions. In the subsequent 10 years, first as a
post-doctoral fellow and later as an assistant staff scientist
in the laboratory of Professor Michal Schwartz at the Weizmann
Institute, she studied the physiological aspects of post-traumatic
neuronal survival. Mr. Rome is a Certified Public Accountant (CPA) who earned
both a B.A. in Accounting and Economics as well as an MBA from
Tel-Aviv University. Before joining Proneuron, he served as
the Corporate Controller of Scitex Vision Ltd., a fully owned
subsidiary of Scitex Corporation Ltd. (Nasdaq: SCIX) and as
Controller for MMD Technologies Israel Ltd. He has also held
several positions with PricewaterhouseCoopers. Dr. David Snyder,
VP Clinical Development
Dr. Snyder earned a Ph.D. in Medical Biochemistry from the
Hebrew University in Jerusalem, in addition to post-doctoral
credentials in neurobiology from Duke University. Dr. Snyder
brings to Proneuron a wealth of experience gained while working
in international pharmaceutical and biotechnology companies
in the US and in Israel. Prior to joining Proneuron, Dr. Snyder
served as Collgard Biopharmaceuticals' VP of Drug Development.
At Collgard, Dr. Snyder was responsible for all regulatory,
clinical and manufacturing strategies and programs. Prior to
Collgard, Dr. Snyder managed Teva Pharmaceutical Industries'
(Nasdaq: TEVA) clinical programs in neurodegenerative diseases
before creating and heading the global clinical operations unit
for the Innovative R&D Division. He also held several positions
in the U.S. Clinical and Regulatory Affairs group at Gensia
Pharmaceuticals. Prof. Michal
Schwartz, Scientific Founder
Prof. Schwartz earned a Ph.D. in chemical immunology from The Weizmann Institute of Science, Rehovot, Israel, in 1977. After completing her post-doctoral studies on the immunology of myasthenia gravis in the laboratory of Professor Sara Fuchs at the Weizmann Institute and on nerve regeneration in the laboratory of Professor Bernard Agranoff at the University of Michigan, she was appointed in 1980 to be a Senior Scientist in the Department of Neurobiology at the Weizmann Institute. In 1985, she was promoted to Associate Professor with tenure. In 1988, she served as a Visiting Associate Professor in the Department of Anatomy at the Medical College of Pennsylvania, and in the same year was appointed incumbent of the Maurice and Ilse Katz Professorial Chair in Neuroimmunology at The Weizmann Institute of Science. In 1998, she was appointed Professor of Neuroimmunology at the Weizmann Institute. Her publications number more than 150 peer-reviewed articles, as well as many invited reviews in highly ranked journals. Prof. Schwartz has received many prestigious awards for her research. In 2000, she was named Career Woman of the Year in Israel. In 2001, she was invited to deliver the 22nd Peter and Eva Safar Annual Lecture in Medical Sciences in Humanities at the University of Pittsburgh School of Medicine. She was the recipient of the 2002 Friedenwald Award from ARVO (Association for Research in Vision and Ophthalmology) for her outstanding contribution to vision research and ophthalmology. Prof. Schwartz is a member of the scientific advisory boards of several distinguished national and international foundations and organizations. Disclaimer | Site Map | Home Page| Contact Us
|